Table 2.
Clinical examples of the OS model.
| All | Surgery ± Radiotherapy | Chemoradiotherapy | ||||
|---|---|---|---|---|---|---|
| 3-year | 5-year | 3-year | 5-year | 3-year | 5-year | |
| Biomarker panel | OS (%) | OS (%) | OS (%) | OS (%) | OS (%) | OS (%) |
| HPV+, p16+, survivin-low, TILs-high | 96.77 | 96.77 | 100.00 | 100.00 | 100.0 | 100.00 |
| HPV+, p16+, survivin-high, TILs-high | 89.93 | 89.93 | 95.65 | 95.65 | 90.40 | 90.40 |
| HPV+, p16+, survivin-low, TILs-low | 86.23 | 78.84 | 91.48 | 81.25 | 90.00 | 82.50 |
| HPV+, p16+, survivin-high, TILs-low | 84.79 | 77.35 | 94.03 | 79.00 | 88.54 | 85.26 |
| HPV−, p16−, survivin-low, TILs-high | 40.00 | 30.00 | 50.00 | 33.33 | 20.00 | 20.00 |
| HPV−, p16−, survivin-high, TILs-high | 66.67 | 42.86 | 85.71 | 68.57 | 57.14 | NA |
| HPV−, p16−, survivin-low, TILs-low | 49.35 | 36.93 | 58.27 | 40.06 | 51.29 | 43.14 |
| HPV−, p16−, survivin-high, TILs-low | 41.91 | 34.68 | 50.18 | 50.18 | 36.44 | 32.80 |
Note: This table demonstrates the 3- and 5-year OS for the subjects with different combinations of biomarker signatures, having received surgery±radiotherapy or radical chemoradiotherapy.